Deprecated: Creation of dynamic property WhitelabelOptions::$_title is deprecated in /home/grassnews/public_html/wp-content/themes/zox-news/admin/admin-page.php on line 79
EVI Industries Sets Records for Revenue and Gross Profit During the Third Quarter – GrassNews
Connect with us

/home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 153
">
Warning: Undefined array key 0 in /home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 153

Warning: Attempt to read property "cat_name" on null in /home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 153

EVI Industries Sets Records for Revenue and Gross Profit During the Third Quarter

Published

on

Reading Time: 8 minutes

MIAMI–(BUSINESS WIRE)–EVI Industries, Inc. (NYSE American: EVI) announced today its results
for the nine and three-month periods ended March 31, 2019. The results,
including record revenue and gross profit for both the nine and
three-month periods ended March 31, 2019, and record Adjusted EBITDA for
the nine-month period ended March 31, 2019, reflect the Company’s
consistent execution of its buy-and-build growth strategy.

Financial Performance

(compared to the same period of the prior fiscal year)

Three Month Results

Advertisement
Stake.com
  • Revenue increased 36% to a record $59 million,
  • Gross profit increased 20% to a record $13 million,
  • Operating income was $1.1 million compared to $1.9 million,
  • Net income was $0.5 million compared to $1.1 million, and
  • Adjusted EBITDA was $2.3 million compared to $2.8 million.

Nine Month Results

  • Revenue increased 54% to a record $163 million,
  • Gross profit increased 45% to a record $37 million,
  • Operating income was $4.6 million compared to $5.1 million,
  • Net income was $2.5 million compared to $3.2 million, and
  • Adjusted EBITDA increased 8.0% to a record $8 million.

Long-Term Growth Strategy

EVI is focused on long-term growth and increasing shareholder value over
time. In furtherance of these goals, EVI continues to thoughtfully
execute its growth strategy, including pursuing investments with respect
to: (1) the acquisition of quality and complementary businesses, (2)
organic growth opportunities, and (3) the realization of improved
efficiency and productivity through investments in advanced technologies.

Henry M. Nahmad, EVI’s CEO, said: “The strength of our Company is the
depth of experience and success among our leaders. Our financial
performance reflects our continued execution of our buy-and-build growth
strategy and the deployment of capital across wide-ranging growth
initiatives undertaken by the entrepreneurs that lead our businesses. We
believe these investments will have a positive impact on achieving our
long-term growth and shareholder value goals.”

Revenues

For the nine and three-month periods ended March 31, 2019, revenues
increased $57.4 million, or 54%, to a record $163 million and increased
$15.6 million, or 36%, to a record $59 million, respectively. The
increase in revenue was primarily due to the results of operations of
acquired businesses that were not consolidated into the Company’s
financial statements for all or part of the prior periods.

Gross Profit and Gross Margin

Advertisement
Stake.com

For the nine and three-month periods ended March 31, 2019, gross profit
increased $11.4 million, or 45%, to a record $37 million and increased
$2.3 million, or 20%, to a record $13 million, respectively. For the
nine and three-month periods ended March 31, 2019, gross margin
decreased from 24.0% to 22.5% and from 25.6% to 22.6%, respectively.

Given EVI’s goal of long-term growth and its investments and initiatives
in furtherance of that goal, the Company believes that its increase in
equipment sales provides a strong foundation for the Company to further
strengthen its customer relationships, including that they should in the
future result in higher gross margin opportunities from the sale of
parts, accessories, supplies, and technical services related to the
equipment. It is important to note, however, that from time to time the
Company enters into longer-term contracts to fulfill large complex
laundry projects for divisions of the federal government where the
nature and structure of such contracts may result in a lower gross
margin as compared to other equipment sales. Despite the potential for a
lower gross margin from such longer-term contracts, the Company believes
that the long-term benefit from the increase in its installed equipment
will outweigh the possible short-term impact to gross margin. As such,
the decrease in gross margin described above was primarily due to the
Company’s increased engagement in longer-term federal government
contracts during the current period. Excluding these longer-term federal
government contracts, gross margin for the nine and three-month periods
ended March 31, 2019 decreased 0.8% to 25.4% and 1.9% to 25.0%,
respectively. This remaining decrease in gross margin is attributable to
typical changes in product mix. Despite these decreases, the Company
generated record gross profit dollars during the current periods.

Operating Expenses

Operating expenses increased $11.9 million, or 58.4%, and $3.0 million,
or 32.6%, for the nine and three-month periods ended March 31, 2019,
respectively. For the current periods, the increase in operating
expenses is largely attributed to expenses incurred by the Company in
connection with its growth strategy: (1) operating expenses related to
the six businesses acquired during the current fiscal year, (2)
additional operating expenses at each of those acquired businesses aimed
to support future growth, (3) an increase in total headcount of 178, of
which 78% were planned increases in sales and service related
professionals, and (4) a 64% increase in operating expenses directly
related to the Company’s growth and acquisition efforts. EVI believes
these expenses will have a positive impact on achieving the Company’s
long-term growth goals.

Acquisition Growth

Advertisement
Stake.com

During the nine-month period ended March 31, 2019, the Company continued
the execution of its long-term buy-and-build growth strategy with the
acquisition of six businesses in the commercial laundry industry. The
acquired businesses increased the Company’s presence and market share in
Florida (2 businesses), Texas (2 businesses), and the Northwest (1
business). Additionally, EVI expanded into the Northeast with the
acquisition of PAC Industries during the three-month period ended March
31, 2019. PAC is a distributor and service provider to the commercial,
industrial, and vended laundry industry based in Harrisburg,
Pennsylvania. PAC employs 60 professionals, of which 44 are dedicated to
sales and service functions serving thousands of customers by offering a
comprehensive suite of products as well as installation and maintenance
services.

Mr. Nahmad commented: “PAC has a longstanding history of providing
world-class laundry solutions and we are honored to be a part of their
family. Their success is the result of quality relationships, a broad
product range, and great service. Consistent with our approach to
maintain business continuity, PAC will operate as a subsidiary of EVI
under its present name and leadership team, while we will provide them
the human, financial, and technological resources to assist them in
achieving their growth plans.”

Special Cash Dividend

During the three-month period ended March 31, 2019, the Company paid a
special cash dividend of $0.13 per share on EVI’s common stock, an 8.3%
increase over EVI’s special cash dividend paid in January 2018. The
dividend was paid on January 8, 2019 to stockholders of record at the
close of business on December 26, 2018.

EVI to Attend Baird 2019 Global Consumer, Technology, and Services
Conference on June 4-6, 2019

Advertisement
Stake.com

The Company will attend and host one-on-one meetings with interested
investors during the conference dates. Conference participation is by
invitation only and registration is mandatory. Additional information
will be provided.

Use of Non-GAAP Financial Information

In this press release, EVI discloses the non-GAAP financial measure of
Adjusted EBITDA, which EVI defines as earnings before interest, taxes,
depreciation, amortization, and amortization of share-based
compensation. Adjusted EBITDA is determined by adding interest expense,
income taxes, depreciation, amortization, and amortization of
share-based compensation to net income as shown in the attached
Condensed Consolidated Earnings before Interest, Taxes, Depreciation,
Amortization, and Amortization of Share-based Compensation. EVI
considers Adjusted EBITDA to be an important indicator of its operating
performance. Adjusted EBITDA is also used by companies, lenders,
investors and others because it excludes certain items that can vary
widely across different industries or among companies within the same
industry. For example, interest expense can be dependent on a company’s
capital structure, debt levels and credit ratings, and the tax positions
of companies can vary because of their differing abilities to take
advantage of tax benefits and because of the tax policies of the
jurisdictions in which they operate. Adjusted EBITDA should not be
considered as an alternative to net income or any other measure of
financial performance or liquidity, including cash flow, derived in
accordance with GAAP, or to any other method of analyzing EVI’s results
as reported under GAAP. In addition, EVI’s definition of Adjusted EBITDA
may not be comparable to definitions of Adjusted EBITDA or other
similarly titled measures used by other companies.

About EVI Industries

EVI Industries, Inc., through its wholly-owned subsidiaries, is a
distributor that generates revenues by selling, leasing or renting,
through its extensive sales organization, commercial, industrial and
vended laundry, dry-cleaning, and material handling equipment, steam and
hot water boilers, water reuse and filtration systems, and related
replacement parts and accessories. Additionally, the Company designs,
plans, and installs turn-key laundry, dry cleaning, boiler, and water
filtration systems and provides maintenance services through its robust
technical service organization.

Advertisement
Stake.com

The Company’s customers include retail, commercial, industrial,
institutional, and government customers. Purchases made by customers
range from parts and accessories, to single or multiple units of
equipment, to large complex systems, as well as installation and
maintenance services. The Company believes that the increase in
equipment sales provides a strong foundation for the Company to further
strengthen its customer relationships, including that they may in the
future result in higher gross margin opportunities from the sale of
parts, accessories, supplies, and technical services related to the
equipment.

Safe Harbor Statement

Except for the historical matters contained herein, statements in this
press release are forward-looking and are made pursuant to the safe
harbor provisions of the Private Securities Litigation Reform Act of
1995. Forward-looking statements are subject to a number of known and
unknown risks and uncertainties that may cause actual results, trends,
performance or achievements of EVI, or industry trends and results, to
differ from the future results, trends, performance or achievements
expressed or implied by such forward-looking statements. These risks and
uncertainties include, among others, the risks related to EVI’s
business, results (including revenues, gross profit, gross margin and
operating expenses), financial condition, prospects, and growth strategy
and plans, risks associated with EVI’s buy-and-build growth strategy,
including that EVI may not be successful in identifying or consummating
acquisitions or other strategic opportunities where or when expected, or
at all, that acquisition and other strategic opportunities may not be
available to EVI to the extent anticipated or at all, that the potential
benefits of transactions may not be realized to the extent anticipated
or at all, integration risks, risks related to indebtedness incurred in
connection with transactions, dilution experienced by EVI’s stockholders
as a result of shares issued in connection with transactions, risks
related to the business, operations and prospects of acquired
businesses, their ability to achieve growth and EVI’s ability to support
growth efforts, risks related to EVI’s and its acquired businesses’
relationships with principal suppliers and customers and the impact that
the loss of any principal supplier or customer could have on EVI’s
results and financial condition, risks related to EVI’s ability to
successfully build its existing operations, risks related to organic
growth initiatives, risks that investments and expenses may not result
in the benefits anticipated, including long-term growth and increases in
shareholder value, risks that investments in advanced technologies may
not result in the realization of improved efficiency and productivity,
risks that equipment sales may not result in the ancillary benefits
anticipated, including that they not lead to increases in higher gross
margin sale of parts, accessories, supplies, and technical services
related to the equipment, and the risk that the benefit of lower gross
margin equipment sales under longer-term federal government contracts
will not outweigh the possible short-term impact to gross margin, and
other economic, competitive, governmental, technological and other risks
and factors, including those discussed in the Company’s filings with the
Securities and Exchange Commission, including, without limitation, the
Company’s Annual Report on Form 10-K for the fiscal year ended June 30,
2018. Many of these risks and factors are beyond EVI’s control. In
addition, dividends are subject to declaration by EVI’s Board of
Directors based on factors deemed relevant by it from time to time, may
be restricted by the terms of EVI’s indebtedness, and may not be paid in
the future, whether with the frequency or in the amounts previously paid
or at all. Further, past performance of EVI and its acquired businesses
and perceived trends may not be indicative of future results. EVI
cautions that the foregoing factors are not exclusive. The reader should
not place undue reliance on any forward-looking statement, which speaks
only as of the date made. EVI does not undertake to, and specifically
disclaims any obligation to, update or supplement any forward-looking
statement, whether as a result of changes in circumstances, new
information, subsequent events or otherwise, except as may be required
by law.

EVI Industries, Inc.

               
Condensed Consolidated Results of Operations (in thousands, except
per share data) (Unaudited)
       

9-Months

Advertisement
Stake.com

Ended

9-Months

Ended

3-Months

Ended

Advertisement
Stake.com

3-Months

Ended

3/31/19 3/31/18 3/31/19 3/31/18
 
Revenues $163,436 $105,995 $59,290 $43,673
Cost of Sales 126,615   80,604   45,867   32,500
Gross Profit 36,821 25,391 13,423 11,173
SG&A 32,180   20,313   12,316   9,286
Operating Income 4,641 5,078 1,107 1,887
Interest Expense, net 942   376   403   193
Income before Income Taxes 3,699 4,702 704 1,694
Provision for Income Taxes 1,172   1,493   238   558
Net Income $2,527   $3,209   $466   $1,136
 
Net Income per Share
Basic $0.20 $0.28 $0.04 $0.10
Diluted $0.20 $0.27 $0.04 $0.09
 
Weighted Average Shares Outstanding
Basic 11,463 10,728 11,666 11,020
Diluted 11,960 11,145 12,145 11,519
 

The following table reconciles net income, the most comparable GAAP
financial measure, to Adjusted EBITDA.
EVI Industries, Inc.

Condensed Consolidated Earnings before Interest, Taxes,
Depreciation, Amortization, and Amortization of

Share-based Compensation (in thousands) (Unaudited)

Advertisement
Stake.com
       

9-Months

Ended

9-Months

Ended

3-Months

Advertisement
Stake.com

Ended

3-Months

Ended

3/31/19 3/31/18 3/31/19 3/31/18
 
Net Income $2,527 $3,209 $466 $1,136
Provision for Income Taxes 1,172 1,493 238 558
Interest Expense 942 376 403 193
Depreciation and Amortization 1,894 1,023 739 476
Amortization of Share-based Compensation 1,287   1,164   449   391
Adjusted EBITDA $7,822   $7,265   $2,295   $2,754

Contacts

Advertisement
Stake.com

EVI Industries, Inc.
Henry M. Nahmad (305) 754-8676

Michael Steiner (305) 754-8676


Warning: Undefined array key 0 in /home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 493

Warning: Attempt to read property "cat_ID" on null in /home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 493

Innocan

Innocan Pharma Submits Investigational New Animal Drug Application to FDA’s Veterinary Center

Published

on

innocan-pharma-submits-investigational-new-animal-drug-application-to-fda’s-veterinary-center

HERZLIYA, Israel and CALGARY, AB, July 26, 2024 /PRNewswire/ — Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (“Innocan” or the “Company”), a pioneer in the pharmaceutical and biotechnology industries, is pleased to announce that the FDA’s Center for Veterinary Medicine (CVM) has granted the Company a sponsor fee waiver and assigned an Investigational New Animal Drug (INAD) number for its LPT-CBD (Liposome Platform Technology-Cannabidiol) product. This represents a significant step for the Company, as an INAD designation facilitates correspondence and data exchange with CVM to support LPT-CBD development as a new veterinary drug.

 

 

The Company further announced that following the assessment of LPT-CBD’s scientific package, the CVM recognized Innocan’s contribution to pursuing innovative animal drug products and technology and granted the company a sponsor fee waiver for fiscal year 2024.  

Innocan’s LPT-CBD is a proprietary drug delivery platform designed to provide prolonged-release CBD for chronic pain and well-being management in animals. Over the past year, repeated administration of LPT-CBD in dogs and other animals has demonstrated both efficacy and tolerability, providing sufficient evidence for the INAD application.

Advertisement
Stake.com

“We are thrilled by CVM’s response,” said Prof. Chezy Barenholz, CSO of Innocan Pharma. “The granted INAD will allow us to advance the investigational studies of LPT-CBD and share knowledge to support future discussions with CVM on LPT-CBD’s development plan. Moreover, the fee waiver, granted by CVM, supports our development and pursuit of innovative animal drug products and technology, further validating our approach and potential impact in veterinary medicine.”

Dr. Eyal Kalo, R&D Director at Innocan, added, “LPT-CBD is a unique technology that has proven itself worthy of the INAD fee waiver granted by CVM. This will streamline our efforts to deliver a unique solution for chronic pain management to the animal market.”

About Innocan Pharma:
Innocan is a pharmaceutical tech company that operates under two main segments: Pharmaceuticals and Consumer Wellness. In the Pharmaceuticals segment, Innocan focuses on developing innovative drug delivery platform technologies comprises with cannabinoids science, to treat various conditions to improve patients’ quality of life. This segment involves two drug delivery technologies: (i) LPT CBD-loaded liposome platform facilitating exact dosing and the prolonged and controlled release of CBD into the blood stream. The LPT delivery platform research is in the preclinical trial phase for two indications: Epilepsy and Pain Management. In the Consumer Wellness segment, Innocan develops and markets a wide portfolio of innovative and high-performance self-care products to promote a healthier lifestyle. Under this segment Innocan has established a Joint Venture by the name of BI Sky Global Ltd. that focuses developing on advanced targeted online sales. https://innocanpharma.com/

Contact Information:

For Innocan Pharma Corporation:
Iris Bincovich, CEO
+1 5162104025
+972-54-3012842
+442037699377
info@innocanpharma.com 

Advertisement
Stake.com

NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATION SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

Caution Regarding Forward-Looking Information

Certain information set forth in this news release, including, without limitation, the Company’s plans for human trials of its LPT-CBD platform, is forward-looking information within the meaning of applicable securities laws. By its nature, forward-looking information is subject to numerous risks and uncertainties, some of which are beyond Innocan’s control. . The forward-looking information contained in this news release is based on certain key expectations and assumptions made by Innocan, including expectations and assumptions concerning the anticipated benefits of the products, satisfaction of regulatory requirements in various jurisdictions and satisfactory completion of production and distribution arrangements.

Forward-looking information is subject to various risks and uncertainties that could cause actual results and experience to differ materially from the anticipated results or expectations expressed in this news release. The key risks and uncertainties include but are not limited to: global and local (national) economic, political, market and business conditions; governmental and regulatory requirements and actions by governmental authorities; and potential disruption of relationships with suppliers, manufacturers, customers, business partners and competitors. There are also risks that are inherent in the nature of product distribution, including import/export matters and the failure to obtain any required regulatory and other approvals (or to do so in a timely manner). The anticipated timeline for entry to markets may change for a number of reasons, including the inability to secure necessary regulatory requirements, or the need for additional time to conclude and/or satisfy the manufacturing and distribution arrangements. As a result of the foregoing, readers should not place undue reliance on the forward-looking information contained in this news release. A comprehensive discussion of other risks that impact Innocan can be found in Innocan’s public reports and filings which are available under Innocan’s profile at www.sedarplus.ca.

Readers are cautioned that undue reliance should not be placed on forward-looking information as actual results may vary materially from the forward-looking information. Innocan does not undertake to update, correct or revise any forward-looking information as a result of any new information, future events or otherwise, except as may be required by applicable law.

Advertisement
Stake.com

Logo: https://mma.prnewswire.com/media/2046271/3968398/Innocan_Pharma_Corporation_Logo.jpg

 

Cision View original content:https://www.prnewswire.co.uk/news-releases/innocan-pharma-submits-investigational-new-animal-drug-application-to-fdas-veterinary-center-302207435.html

Continue Reading

Cannabis

Verano Announces the Opening of Zen Leaf Fairless Hills, the Company’s Newest Affiliated Dispensary in Pennsylvania, in Prime New Location

Published

on

  • Zen Leaf Fairless Hills, the Company’s newest affiliated dispensary in Pennsylvania, relocated from its former home in Chester to 203 Lincoln Highway, a busy thoroughfare with daily traffic of over 17,000 vehicles per day1
  • As the first medical cannabis dispensary in the city, Zen Leaf Fairless Hills will offer an elevated experience for area patients, including increased convenience and accessibility with numerous point-of-sale stations and kiosks for seamless in-store browsing and ordering
  • Verano’s active operations span 13 states, comprised of 142 dispensaries and 13 cultivation and processing facilities with more than 1 million square feet of cultivation capacity

CHICAGO, July 26, 2024 (GLOBE NEWSWIRE) — Verano Holdings Corp. (Cboe CA: VRNO) (OTCQX: VRNOF) (“Verano” or the “Company”), a leading multi-state cannabis company, today announced the opening of Zen Leaf Fairless Hills in Pennsylvania on Friday, July 26th, following a ceremonial ribbon cutting at 11 a.m. local time. Zen Leaf Fairless Hills is located at 203 Lincoln Highway and will be open Monday through Saturday from 9 a.m. to 8 p.m. and Sunday from 10 a.m. to 6 p.m. local time.

The dispensary is located in Bucks County, the fourth largest county in the Commonwealth with a total population of over 630,0002 residents. To increase accessibility and convenience, Zen Leaf Fairless Hills features large in-store kiosks and numerous point-of-sale stations to enhance the browsing and ordering experience for patients. To celebrate the grand opening of Zen Leaf Fairless Hills and following a ceremonial ribbon cutting, patients will be greeted with complimentary deals and doorbusters on featured branded products.

“We are excited to bring the Zen Leaf experience to local patients in Fairless Hills, where our talented team members will continue to deliver hospitality-driven care and top-quality products for local patients,” said George Archos, Verano Founder and Chief Executive Officer. “As the Pennsylvania medical cannabis patient population continues to grow, we are grateful for the opportunity to deepen our roots in Bucks County at our newest Zen Leaf location in the Commonwealth, and look forward to providing a warm and welcoming environment for current and future patients.”

Zen Leaf Fairless Hills adds another convenient outlet for Philadelphia area patients, and solidifies Verano’s footprint in the state as one of the Company’s 18 affiliated Pennsylvania dispensaries. Verano’s Pennsylvania operations also include a state-of-the-art 62,000 square foot cultivation and processing facility in Chester, where the Company produces its signature Verano Reserve flower and Troches, concentrates and vapes; (the) Essence and Savvy flower and extracts; and Avexia RSO cannabis oil and topicals. For additional convenience and accessibility, patients can choose to order ahead at ZenLeafDispensaries.com for express in-store pickup.

About Verano

Verano Holdings Corp. (Cboe CA: VRNO) (OTCQX: VRNOF), one of the U.S. cannabis industry’s leading companies based on historical revenue, geographic scope and brand performance, is a vertically integrated, multi-state operator embracing a mission of saying Yes to plant progress and the bold exploration of cannabis. Verano provides a superior cannabis shopping experience in medical and adult use markets under the Zen Leaf and MÜV dispensary banners, including Cabbage Club, an innovative annual membership program offering exclusive benefits for cannabis consumers. Verano produces a comprehensive suite of high-quality, regulated cannabis products sold under its diverse portfolio of trusted consumer brands including Verano, (the) Essence, MÜV, Savvy, BITS, Encore, and Avexia. Verano’s active operations span 13 U.S. states, comprised of 13 production facilities with over 1,000,000 square feet of cultivation capacity. Learn more at Verano.com.

Advertisement
Stake.com

Contacts:

Media
Verano
Steve Mazeika
VP, Communications
Steve.Mazeika@verano.com

Investors
Verano
Julianna Paterra, CFA
VP, Investor Relations
Julianna.Paterra@verano.com

Forward Looking Statements

This press release contains “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Such forward-looking statements are not representative of historical facts or information or current condition, but instead represent only the Company’s beliefs regarding future events, plans, strategies, or objectives, many of which, by their nature, are inherently uncertain and outside of the Company’s control. Generally, such forward-looking statements can be identified by the use of forward-looking terminology such as “plans”, “expects” or “does not expect”, “is expected”, “budget”, “future”, “scheduled”, “estimates”, “forecasts”, “projects,” “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases, or may contain statements that certain actions, events or results “may”, “could”, “would”, “might” or “will be taken”, “will continue”, “will occur” or “will be achieved”. Forward-looking statements involve and are subject to assumptions and known and unknown risks, uncertainties, and other factors which may cause actual events, results, performance, or achievements of the Company to be materially different from future events, results, performance, and achievements expressed or implied by forward-looking statements herein, including, without limitation, the risk factors described in the Company’s annual report on Form 10-K for the year ended December 31, 2023, its quarterly report on Form 10-Q for the quarter ended March 31, 2024 and any subsequent quarterly reports on Form 10-Q, in each case, filed with the U.S. Securities and Exchange Commission at www.sec.gov. The Company makes no assurances and cannot predict the outcome of all or any part of the on-going litigation with Goodness Growth referenced in this press release, including whether the Company will prevail on its Notice of Application and its counterclaim, or whether Goodness Growth will prevail on its claim for damages against the Company. The forward-looking statements contained in this press release are made as of the date of this press release, and the Company does not undertake to update any forward-looking information or forward-looking statements that are contained or referenced herein, except as may be required in accordance with applicable securities laws. All subsequent written and oral forward-looking information and statements attributable to the Company or persons acting on its behalf is expressly qualified in its entirety by this notice regarding forward-looking information and statements.

Advertisement
Stake.com

###


1 Pennsylvania Department of Transportation
2 United States Census Bureau

Continue Reading

Cannabis

Unlocking New Horizons in Health: TNR, The Niche Research Reveals the Transformative Power of Minor Cannabinoids

Published

on

Wilmington, Delaware, July 25, 2024 (GLOBE NEWSWIRE) — Minor cannabinoids refer to the lesser-known compounds found in the cannabis plant, distinct from the well-known THC (tetrahydrocannabinol) and CBD (cannabidiol). While THC and CBD dominate the market, minor cannabinoids such as CBG (cannabigerol), CBC (cannabichromene), and CBN (cannabinol) are gaining attention for their potential therapeutic benefits. These compounds are extracted from both marijuana and hemp plants, with varying legal restrictions depending on their THC content. The minor cannabinoids market is poised for significant growth, driven by increasing consumer awareness and demand for alternative health and wellness products. As regulatory environments around cannabis products evolve, companies are exploring the potential of minor cannabinoids in various applications, including pharmaceuticals, nutraceuticals, cosmetics, and food and beverages.

Minor cannabinoids are being researched for their potential therapeutic effects, including anti-inflammatory, analgesic, and neuroprotective properties. This versatility facilitates product diversification in various industries. Companies are investing in research and development to create novel formulations and delivery methods for minor cannabinoids. This includes nano-emulsions, encapsulation technologies, and controlled-release systems to enhance bioavailability and efficacy. For example, in January 2022, CBDA + CBGA Tincture a new product was launched by Hometown Hero CBD. This 30ml tincture contains 600mg each of CBGA, CBDA, CBG, and CBD. Derived from hemp, the cannabinoids in this tincture comply with legal requirements across all 50 states in the USA. There is an increasing consumer preference for natural as well as plant-based remedies, which in turn is driving the demand for cannabinoid-infused products. This trend is particularly strong among younger demographics seeking alternatives to traditional pharmaceuticals. Evolving regulatory frameworks, particularly in regions like North America and Europe, are creating opportunities for legal market expansion. Regulatory clarity is crucial for market participants to navigate compliance and market entry.

Global Minor Cannabinoids Market: Key Datapoints
 

Market Value in 2023

Advertisement
Stake.com
 

US$ 17.8 Bn

 

Market Value Forecast by 2034

 
Advertisement
Stake.com

US$ 42.3 Bn

 

Growth Rate

 

 
Advertisement
Stake.com

8.2%

 

Historical Data

 

 
Advertisement
Stake.com

2016 – 2022

 

Base Year

 

 
Advertisement
Stake.com

2023

 

Forecast Data

 

 
Advertisement
Stake.com

2024 – 2034

Increasing consumer interest in health and wellness products, coupled with the perceived therapeutic benefits of cannabinoids, is a major driver of market growth. Progressive cannabis legalization in various parts of the world, including the United States and parts of Europe, is expanding the addressable market for minor cannabinoids. Significant investments in research and development by pharmaceutical and biotechnology companies are accelerating product innovation and clinical trials. The market remains fragmented with opportunities for new entrants and niche players to introduce specialized products catering to specific consumer needs.

Get Sample Copy of the Report

The COVID-19 pandemic initially disrupted supply chains and retail channels for minor cannabinoids products. However, the crisis also underscored the importance of health and wellness, leading to increased interest in natural remedies, including cannabinoids. As economies recover, the market is expected to rebound stronger.

The geopolitical tensions, such as the Russia-Ukraine conflict, have also affected global markets, including the minor cannabinoids sector. Fluctuating currency values, supply chain disruptions, and geopolitical uncertainty have impacted production and distribution channels. However, the long-term impact will depend on geopolitical developments and their influence on global trade and regulatory environments.

Advertisement
Stake.com

The minor cannabinoids market presents significant opportunities for growth and innovation, driven by evolving consumer preferences, regulatory advancements, and expanding research initiatives. Companies that can navigate regulatory complexities, invest in research and development, and respond to shifting consumer trends are well-positioned to capitalize on this emerging market. As the market matures, collaboration across sectors and regions will be crucial in unlocking the full potential of minor cannabinoids in various industries worldwide.

Visit our Homepage

Global Minor Cannabinoids Market: Key Takeaways of the Report

  • Cannabigerol (CBG) segment by product type is expected to grow at a CAGR of 6.7% in the minor cannabinoids market due to increasing research highlighting its potential therapeutic benefits, including anti-inflammatory, antimicrobial, and neuroprotective properties. As consumer awareness grows and regulatory environments become more favorable, there is heightened interest in CBG-based products for their diverse health applications, ranging from skincare to pharmaceutical formulations, driving sustained market demand and expansion.
  • Pharmaceutical segment by application, leads the minor cannabinoids market with a significant revenue share of 35.8% owing to growing recognition of cannabinoids’ potential in therapeutic applications. Cannabinoids like CBD, CBG, and others show promise in treating conditions such as epilepsy, chronic pain, and anxiety disorders, backed by increasing clinical research and favorable regulatory developments. Pharmaceutical companies are investing heavily in cannabinoid-based drug development, driving market growth as they seek to capitalize on these compounds’ efficacy and market potential in addressing unmet medical needs.
  • In 2023, Latin America is anticipated as fastest growing region in the global minor cannabinoids market due to evolving regulatory landscapes favoring cannabis legalization and cultivation. This shift is fostering a burgeoning industry infrastructure for cannabis extraction and product development. Additionally, increasing consumer acceptance of cannabinoid-based products for medicinal and wellness purposes is driving market expansion. With a vast potential consumer base and supportive regulatory frameworks, Latin America presents significant growth opportunities for companies seeking to enter or expand within the minor cannabinoids market.

Key Development:

  • In December 2023, Rare Cannabinoid Company introduced Uplift Gummies infused with THC and THCV. These gummies combine the relaxing properties of Delta-9-THC with the energizing and appetite-controlling effects of CBD and THCV.
  • In October 2022, High Tide Inc., a cannabis retailer, announced that its Colorado-based subsidiary, NuLeaf Naturals, had launched plant-based softgels and full-spectrum multicannabinoid oil in Manitoba. The products feature CBC, CBD, CBG, Delta-9 tetrahydrocannabinol (Delta 9), and CBN.

Browse Related Category Reports

Global Minor Cannabinoids Market:

  • Aurora Europe GmbH
  • BulKanna
  • CBD. INC.
  • Fresh Bros Hemp Company
  • GCM Holdings, LLC (Global Cannabinoids)
  • GenCanna.
  • High Purity Natural Products.
  • Laurelcrest
  • Mile High Labs
  • PBG Global
  • Rhizo Sciences
  • ZERO POINT EXTRACTION, LLC
  • Other Industry Participants

Global Minor Cannabinoids Market

By Product Type

Advertisement
Stake.com
  • Cannabigerol (CBG)
  • Cannabichromene (CBC)
  • Cannabinol (CBN)
  • Cannabidivarin (CBDV)
  • Tetrahydrocannabutol (THCB)
  • Tetrahydrocannabivarin (THCV)
  • Tetrahydrocannabiphorol (THCP)
  • Others

By Application

  • Pharmaceutical
    • Pain Management
    • Mental Health
    • Sleep Disorders
    • Anti-inflammatory
    • Others
  • Nutraceuticals
  • Cosmetics and Personal Care
  • Food and Beverages
  • Others

By Region

  • North America (U.S., Canada, Mexico, Rest of North America)
  • Europe (France, The UK, Spain, Germany, Italy, Nordic Countries (Denmark, Finland, Iceland, Sweden, Norway), Benelux Union (Belgium, The Netherlands, Luxembourg), Rest of Europe)
  • Asia Pacific (China, Japan, India, New Zealand, Australia, South Korea, Southeast Asia (Indonesia, Thailand, Malaysia, Singapore, Rest of Southeast Asia), Rest of Asia Pacific)
  • Middle East & Africa (Saudi Arabia, UAE, Egypt, Kuwait, South Africa, Rest of Middle East & Africa)
  • Latin America (Brazil, Argentina, Rest of Latin America)  

Consult with Our Expert:

Jay Reynolds

The Niche Research

Japan (Toll-Free): +81 663-386-8111

South Korea (Toll-Free): +82-808- 703-126

Saudi Arabia (Toll-Free): +966 800-850-1643

Advertisement
Stake.com

United Kingdom: +44 753-710-5080

United States: +1 302-232-5106

Email: askanexpert@thenicheresearch.com

Website: www.thenicheresearch.com

Advertisement
Stake.com
Continue Reading
Advertisement
Stake.com

Latest news

Trending on Grassnews

GrassNews.net: Your premier portal for the latest developments in the cannabis industry. We provide timely news, insightful analysis, and in-depth features on everything from legislation changes and business trends, to scientific research and lifestyle topics. Stay informed and navigate the rapidly evolving cannabis landscape with GrassNews.net..

Contact us: sales@hipther.agency

Editorial / PR Submissions

Copyright © 2007 - 2024 Hipther Agency. Registered in Romania under Proshirt SRL, Company number: 2134306, EU VAT ID: RO21343605. Office address: Blvd. 1 Decembrie 1918 nr.5, Targu Mures, Romania